Asahi Kasei obtains license for bone cell therapy product

25 September 2017

Belgium’s Bone Therapeutics (Euronext Brussels: BOTHE) has signed a license agreement granting Japanese drugmaker Asahi Kasei (TYO: 3407) exclusive rights to develop and commercialize the PREOB bone cell therapy product in Japan with an option to negotiate an exclusive license for development and commercialization of PREOB in Korea, China, and Taiwan.

Bone Therapeutics will receive an upfront payment of 1.7 million euros ($2.0 million) from Asahi Kasei and is eligible to receive up to 7.5 million euros from development and commercial milestone payments, as well as tiered royalties based on annual net sales of PREOBin Japan.

The deal was announced late on Friday, but this morning Bone Therapeutics saw its share leap 9.6% to 10.47 euros.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK